Goli, K. J., Desjardins, A., Herndon, J. E., Rich, J. N., Reardon, D. A., Quinn, J. A., … Vredenburgh, J. J. (2007). Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 25). AMER SOC CLINICAL ONCOLOGY.

Goli, K. J., A. Desjardins, J. E. Herndon, J. N. Rich, D. A. Reardon, J. A. Quinn, S. Sathornsumetee, D. A. Bota, H. S. Friedman, and J. J. Vredenburgh. “Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.

Goli KJ, Desjardins A, Herndon JE, Rich JN, Reardon DA, Quinn JA, et al. Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2007.

Goli, K. J., et al. “Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas.” JOURNAL OF CLINICAL ONCOLOGY, vol. 25, no. 18, AMER SOC CLINICAL ONCOLOGY, 2007.

Goli KJ, Desjardins A, Herndon JE, Rich JN, Reardon DA, Quinn JA, Sathornsumetee S, Bota DA, Friedman HS, Vredenburgh JJ. Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2007.